In conclusion, the regulatory mechanisms of FXR and its involvement in the gut-liver axis offer significant clinical and research potential for the prevention and treatment of MASLD and HCC, particularly through multi-target therapeutic approaches. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.